The last 5 years has led to multiple targeted therapy approvals for patients with AML and mutations in IDH1 (ivosidenib [IVO], olutasidenib [OLU]), IDH2 (enasidenib [ENA]), and FLT3 (MIDO, gilteritinib [GILT]). This evidence concerns the gene IDH1 and acute myeloid leukemia.